Ramon Mendez
Nephrology · Woodbridge, VANPI 1235185026
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $604,104 of the $791,314 with a category attached, or 76.3%. 21 manufacturers reported payments, led by Bayer at 47.9% of the total. Among nephrology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,290 payments — averaging $613.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$379K
- Akebia Therapeutics Inc$213K
- AstraZeneca$75K
- Mallinckrodt Enterprises LLC$37K
- Lilly USA, LLC$34K
- Amgen$25K
- plus $28K from 15 others
Across 238 payments — averaging $2909.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$260K
- AstraZeneca$232K
- Bayer$151K
- Sanofi US Services Inc.$40K
- Lexicon Pharmaceuticals, Inc.$5K
- GSK$4K
- plus $74 from 1 others
What the payments were for
- Consulting fees$11,4321%
- Speaking & faculty fees$604,10476%
- Travel & lodging$152,33619%
- Food & beverage$23,0373%
- Education$4050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 474 | $379,066 |
| Akebia Therapeutics Inc | 363 | $213,119 |
| AstraZeneca | 151 | $75,043 |
| Mallinckrodt Enterprises LLC | 79 | $37,165 |
| Lilly USA, LLC | 53 | $33,919 |
| Amgen(2 entities) | 41 | $24,750 |
| Boehringer Ingelheim | 40 | $20,975 |
| Mallinckrodt Hospital Products Inc. | 16 | $4,225 |
| ANI Pharmaceuticals, Inc. | 3 | $1,326 |
| Otsuka America Pharmaceutical, Inc. | 25 | $599 |
| OPKO Pharmaceuticals, LLC | 20 | $407 |
| Ardelyx, Inc. | 6 | $195 |
| Travere Therapeutics, Inc. | 3 | $155 |
| Novo Nordisk | 5 | $128 |
| Vifor Pharma, Inc. | 4 | $95 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Novartis | 1 | $29 |
| GSK | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$791,314 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $63,845 |
| XphozahTenapanor Hcl | 12 | $40,482 |
| KerendiaFinerenone | 28 | $37,356 |
| FarxigaDapagliflozin Propanediol | 27 | $29,162 |
| Atorvastatin Calcium | 25 | $504 |
| Losartan Potassium | 28 | $391 |
| Torsemide | 15 | $390 |
| Amlodipine Besylate | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $33,919 | $63,84538 claims |
| BayerKerendia | $379,066 | $37,35628 claims |
| AstraZenecaFarxiga | $75,043 | $29,16227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 298 nephrology providers in Virginia.
Other nephrology in Woodbridge
- Anish ShahWoodbridge$14K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Ramin TolouianNorfolk$115K
- Mahesh KrishnanMc Lean$115K
- Mitchell RosnerCharlottesville$105K
- Neeraja TandraReston$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.